Literature DB >> 8882375

New hepatitis A vaccines and their role in prevention.

D B Strader1, L B Seeff.   

Abstract

The hepatitis A virus (HAV) accounts for 20 to 25% of clinically apparent hepatitis cases worldwide. It generally causes mild to moderately severe acute illness. The serological prevalence of this virus is high in underdeveloped countries where poor sanitary conditions facilitate the spread of the virus. The Sentinel Counties studies of the Centers for Disease Control in the US have identified a number of factors associated with the acquisition of HAV, including household members, homosexual men, children and caretakers in day-care facilities who come into contact with individuals who are incubating or in the early phases of HAV infection. Poor sanitary conditions, international travel and intravenous drug use promote the transmission of the virus. However, in 40% of cases, no risk factor can be identified. Immune globulin (IG), once used exclusively for the prevention of HAV infection, acts by provoking passive-active immunity. It prevents clinical disease but permits subclinical disease to develop. Unfortunately, IG provides protection for only 3 to 6 months, necessitating repeat inoculation for exposure extending over 180 days. More recently, a number of live-attenuated and formalin-inactivated HAV vaccines have been developed and studied. The vaccines are well tolerated and highly immunogenic, with only mild local adverse reactions. The suggested dose and schedule is 720 ELISA units of inactivated vaccine injected intramuscularly at 0, 1 and 6 months. A single intramuscular dose of 1440 ELISA units followed 6 to 12 months later by a further injection has also been approved by the FDA and is available in several European countries. 90% of vaccines achieve protective levels of anti-HAV after the first injection. Routine use of the HAV vaccine for pre-exposure prophylaxis is expected to replace IG in healthy adults travelling to endemic areas, children in day-care centres, military personnel, homosexual men, healthcare workers and residents in institutions for the mentally disabled.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882375     DOI: 10.2165/00003495-199651030-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  An inactivated hepatitis A virus vaccine prepared from infected marmoset liver.

Authors:  P J Provost; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1978-11

2.  Studies of prototype live hepatitis A virus vaccines in primate models.

Authors:  R A Karron; R Daemer; J Ticehurst; E D'Hondt; H Popper; K Mihalik; J Phillips; S Feinstone; R H Purcell
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

Review 3.  Recent advances in hepatitis A vaccine development.

Authors:  G Siegl; S M Lemon
Journal:  Virus Res       Date:  1990-10       Impact factor: 3.303

4.  Complete nucleotide sequence of a cell culture-adapted variant of hepatitis A virus: comparison with wild-type virus with restricted capacity for in vitro replication.

Authors:  R W Jansen; J E Newbold; S M Lemon
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

5.  Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule.

Authors:  T U Westblom; S Gudipati; C DeRousse; B R Midkiff; R B Belshe
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

6.  Clinical and subclinical hepatitis A occurring after immunoglobulin prophylaxis among Swedish UN soldiers in Sinai.

Authors:  O Weiland; B Niklasson; R Berg; P Lundbergh; L Tideström
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

7.  Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

Authors:  M S Green; D Cohen; Y Lerman; M Sjogren; L N Binn; S Zur; R Slepon; G Robin; C Hoke; W Bancroft
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

8.  Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I.

Authors:  D P Francis; S C Hadler; T J Prendergast; E Peterson; M M Ginsberg; C Lookabaugh; J R Holmes; J E Maynard
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

Review 9.  Atypical clinical manifestations of hepatitis A.

Authors:  E R Schiff
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.

Authors:  J P Bryan; M Nelson
Journal:  Arch Intern Med       Date:  1994-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.